LBPH vs. LASE

Last updated Jun 4, 2026

LBPH (Longboard Pharmaceuticals, Inc.) and LASE (Laser Photonics Corporation) are both stocks. LBPH operates in Biotechnology (Healthcare), while LASE operates in Specialty Industrial Machinery (Industrials). At a 0.06 correlation, their price movements are largely independent.

Performance

LBPH vs. LASE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Longboard Pharmaceuticals, Inc. (LBPH) and Laser Photonics Corporation (LASE). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

LBPH

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

LASE

• 1D: 29.34%
• 1M: 335.69%
• YTD: 26.72%
• 6M: 3.64%
• 1Y: 32.63%
• 3Y*: -2.24%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

LBPH vs. LASE - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022
LBPH Longboard Pharmaceuticals, Inc.	0.00%	0.00%	894.69%	84.97%	-12.37%
LASE Laser Photonics Corporation	26.72%	-57.27%	389.83%	-42.16%	-20.93%

Correlation

The correlation between LBPH and LASE is 0.06, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (3Y) Calculated over the trailing 3-year period	0.05
Correlation (All Time) Calculated using the full available price history since Oct 3, 2022	0.06

Fundamentals

Total Revenue (TTM) LBPH : $8.00K LASE : $7.14M
Gross Profit (TTM) LBPH : $4.00K LASE : $2.22M
EBITDA (TTM) LBPH : -$87.45M LASE : -$8.37M

Return for Risk

LBPH vs. LASE — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

LASE

LASE Risk / Return Rank: 60
LASE Sharpe Ratio Rank: 46
LASE Sortino Ratio Rank: 79
LASE Omega Ratio Rank: 77
LASE Calmar Ratio Rank: 49
LASE Martin Ratio Rank: 47

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

LBPH vs. LASE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Longboard Pharmaceuticals, Inc. (LBPH) and Laser Photonics Corporation (LASE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	LBPH	LASE	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	0.14	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	0.03	—

Drawdowns

Drawdown Indicators

	LBPH	LASE	Difference
Max Drawdown Largest peak-to-trough decline	—	-96.80%	—
Max Drawdown (1Y) Largest decline over 1 year	—	-90.76%	—
Max Drawdown (3Y) Largest decline over 3 years	—	-96.80%	—
Current Drawdown Current decline from peak	—	-83.35%	—
Average Drawdown Average peak-to-trough decline	—	-70.16%	—
Ulcer Index Depth and duration of drawdowns from previous peaks	—	61.35%	—

Volatility

Volatility by Period

	LBPH	LASE	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	100.29%	—
Volatility (6M) Calculated over the trailing 6-month period	—	142.09%	—
Volatility (1Y) Calculated over the trailing 1-year period	—	230.98%	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	—	184.60%	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	—	184.60%	—

Dividends

LBPH vs. LASE - Dividend Comparison

Neither LBPH nor LASE has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both LBPH and LASE in my portfolio?

LBPH and LASE have a correlation of 0.06, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.